Comment from Chiesi Farmaceutici S.p.A.

Summary: Chiesi USA, Inc., a pharmaceutical company specializing in rare diseases, supports the draft guidance on the Plausible Mechanism Framework. They argue for greater clarity on evidentiary expectations, the inclusion of platform-based therapeutics, and the ability to use mechanistic evidence as a substitute for natural history data in ultra-rare disease settings.